Viatris (VTRS) has announced encouraging top-line outcomes from its Phase 3 trial in Japan, assessing the safety and efficacy of EFFEXOR in adults diagnosed with generalized anxiety disorder (GAD). The trial successfully met its primary endpoint, highlighting the superiority of venlafaxine's anxiolytic effects over placebo after an 8-week period. Additionally, all seven secondary efficacy endpoints were achieved, reinforcing EFFEXOR's efficacy compared to placebo. Throughout the study, EFFEXOR was largely well-tolerated by participants. The company plans to unveil the comprehensive results from this Phase 3 trial at an upcoming medical conference.
Currently, EFFEXOR is authorized in Japan for treating major depressive disorder in adults and is approved for GAD in over 80 countries globally, excluding Japan.
